Home LiteratureArticle Details
PMID: 7516992 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours.

Lancet (London, England) ·Vol. 344 ·No. 8915 ·1994-07-09 ·Pages 82-6

Li VW, Folkerth RD, Watanabe H, Yu C, Rupnick M, Barnes P, Scott RM, Black PM, Sallan SE, Folkman J

Abstract

Tumour growth is angiogenesis-dependent; brain tumours have more intense neovascularisation than other tumours and produce basic fibroblast growth factor, a potent angiogenic mediator. Because little is known about the release of basic fibroblast growth factor from brain tumours into extracellular fluids, we tested cerebrospinal fluid (CSF) from 26 children and young adults with brain tumours and 18 controls for basic fibroblast growth factor and for proliferative activity on cultured capillary endothelial cells. We also measured the density of microvessels in tumours by immunohistochemical staining. Basic fibroblast growth factor was detected in the CSF of 62% (16 of 26) patients with brain tumours but in none of the controls. Specimens with basic fibroblast growth factor stimulated DNA synthesis of capillary endothelial cells in vitro. Endothelial proliferative activity was blocked by neutralising antibodies to basic fibroblast growth factor. Basic fibroblast growth factor correlated with mitogenic activity in CSF in vitro (p < or = 0.0001), and with density of microvessels in histological sections (p < or = 0.005). A microvessel count of > or = 68 per 200 x field was associated with tumour recurrence (p = 0.005) and with mortality (p = 0.02). Basic fibroblast growth factor in brain tumours may mediate angiogenesis as measured by microvessel density in histological sections, so has potential as both a marker for neoplasia and a target for tumour treatments. Furthermore, evaluation of cerebrospinal fluid basic fibroblast growth factor, along with microvessel quantitation in biopsied tumours, may provide improved prognostic information for the management of patients with brain tumours.

MeSH Terms
Adolescent Adult Brain Neoplasms/cerebrospinal fluid,pathology Cells, Cultured Child Child, Preschool Enzyme-Linked Immunosorbent Assay Fibroblast Growth Factor 2/cerebrospinal fluid Follow-Up Studies Humans Immunohistochemistry Magnetic Resonance Imaging Neoplasm Recurrence, Local/diagnosis Neovascularization, Pathologic/pathology Prognosis Staining and Labeling
Chemicals
Fibroblast Growth Factor 2
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Li V W
Department of Surgery, Children's Hospital, Boston, MA 02115.
Folkerth R D
Watanabe H
Yu C
Rupnick M
Barnes P
Scott R M
Black P M
Sallan S E
Folkman J
Article Info
Journal
Lancet (London, England)
Abbr.
Lancet
ISSN
0140-6736
Published
1994-07-09
Pages
82-6
Language
English
Region
England
NLM ID
2985213R
Subset
IM
Grants
NCI NIH HHS · 5T32CA09535-06 · United States
NCI NIH HHS · CA37395-09 · United States
NINDS NIH HHS · NINDS NS-92-01 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com